Genentech Inc.

Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study (2019) Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, et al. Journal article KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer (2019) Mamounas EP, Geyer CE, Huang CS, Mano MS, Loibl S, Untch M, Wolmark N, et al. Conference contribution LONG-TERM OUTCOME OF TOCILIZUMAB FOR PATIENTS WITH GIANT CELL ARTERITIS: RESULTS FROM PART 2 OF THE GIACTA TRIAL (2019) Stone JH, Bao M, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, et al. Conference contribution EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN THE GIACTA TRIAL (2019) Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, et al. Conference contribution EFFECTS OF BASELINE PREDNISONE DOSE ON REMISSION AND DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS TREATED WITH TOCILIZUMAB IN A PHASE 3 RANDOMIZED CONTROLLED TRIAL (2019) Stone J, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, et al. Conference contribution Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer (2019) Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, et al. Journal article Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease (2019) Lichnog C, Klabunde S, Becker E, Fuh F, Tripal P, Atreya R, Klenske E, et al. Journal article ACUTE PHASE REACTANT LEVELS AND PREDNISONE DOSES AT DISEASE FLARE IN PATIENTS WITH GIANT CELL ARTERITIS: PROSPECTIVE DATA FROM THE GIACTA TRIAL (2019) Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, et al. Conference contribution Glucocorticoid Doses and Acute-Phase Reactants at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab (2019) Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, et al. Journal article Double genetic disruption of lactate dehydrogenases A and B is required to ablate the “Warburg effect” restricting tumor growth to oxidative metabolism (2018) Zdralevic M, Brand A, Di Ianni L, Dettmer K, Reinders J, Singer K, Peter K, et al. Journal article